Skip to main content
Log in

Bleomycin pharmacokinetics in man

I. Intravenous administration

  • Original Papers
  • Bleomycin
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Bleomycin plasma decay kinetics and urinary excretion were studied in nine patients after IV bolus injections of 13.7 to 19.9 U/M2. Radio-immunoassay was used to measure bleomycin in plasma and urine samples. The resulting plasma concentration versus time data for each patient and the combined data obtained from all patients were fitted to a multiexponential equation using a nonlinear regression computer program. Pharmacokinetic parameters derived from the mean of all individual patient parameters and the composite of all plasma decay data were similar. Bleomycin initial and terminal plasma half-lives and volume of distribution for all plasma decay data from eight patients with normal serum creatinies were 24.4±4.0 min, 237.5±8.5 min, and 17.3±1.5 L/M2, respectively. Mean 24-h urinary excretion accounted for 44.8±12.6% of the dose in seven patients who had normal serum creatinine values and complete urine collections. The total body clearance and renal clearance in these seven patients averaged 50.5±4.1 ml/min/M2 and 23.0±1.9 ml/min/M2, respectively. One patient with a serum creatinine of 1.5 mg% (normal 0.7 to 1.3 mg%) who was given 15.6 U/M2 had a terminal plasma halflife of 624 min, a volume of distribution of 36.3 L/M2, and 24-h urinary excretion of 11.6% of the dose. We conclude that bleomycin after intravenous bolus injection has a relatively short terminal phase plasma halflife and relatively large urinary elimination.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Blum, R. H., Carter, S. K., Agre, K.: A clinical review of bleomycin — a new antineoplastic agent. Cancer 31, 903–914 (1972)

    Google Scholar 

  • Boxenbaum, H. G., Riegelman, S., Elashoff, R. M.: Statistical estimations in pharmacokinetics. J. Pharmacokinet. Biopharm. 2, 123–148 (1974)

    Google Scholar 

  • Broughton, A., Strong, J. E.: Radioimmunoassay of bleomycin. Cancer Res. 36, 1418–1421 (1976)

    Google Scholar 

  • Crooke, S. T., Luft, F., Broughton, A., Strong, J., Casson, K., Einhorn, L.: Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal funtion. Cancer 39, 1430–1434 (1977a)

    Google Scholar 

  • Crooke, S. T., Comis, R. L., Einhorn, L. H., Strong, J. E., Broughton, A., Prestayko, A. W.: Effect of variations in renal function on the clinical pharmacology of bleomycin administered as an IV bolus. Cancer Treat. Rep. 61, 1631–1636 (1977b)

    Google Scholar 

  • Deming, W. E.: Statistical Adjustment of Data, pp. 37–48. New York: Dover 1938

    Google Scholar 

  • Fugii, A., Takita, T., Maeda, K., Umezawa, H.: Components of bleomycin. J. Antibiot. (Tokyo) 26, 396–397 (1973a)

    Google Scholar 

  • Fugii, A., Takita, T., Umezawa, H.: Chemistry of bleomycin XI. J. Antibiot. (Tokyo) 26, 398–399 (1973b)

    Google Scholar 

  • Fugita, H., Kimura, K.: Blood level, tissue distribution, excretion and inactivation of bleomycin. In: Progressin Antimicrobiol and Anticancer Chemotherapy, Vol. 2, p. 309. Baltimore: University Park Press 1970

    Google Scholar 

  • Hall, S. W., Broughton, A., Strong, J. E., Benjamin, R. S.: Clinical pharmacology of bleomycin by radioimmunoassay. Clin. Res. 25, 407A (1977)

  • Metzler, C. M.: NONLIN: A computer program for parameter estimation in nonlinear situations. Kalamazoo, Michigan: Upjohn Co. 1969 (Technical Report 7292/69/7292/005)

    Google Scholar 

  • Ohnuma, T., Holland, J. F., Masuda, H., Waligunda, J. A., Goldberg, G. A.: Microbiological assay of bleomycin: inactivation, tissue distribution and clearance. Cancer 33, 1230–1238 (1974)

    Google Scholar 

  • Paladine, W., Cunningham, T. J., Sponzo, R., Donavan, M., Olson, K., Horton, J.: Intracavitary bleomycin in the management of malignant effusions. Cancer 38, 1903–1908 (1976)

    Google Scholar 

  • Sedman, A. J., Wagner, J. G.: CSTRIP. A Fortran IV computer program for obtaining initial polyexponential parameter estimates. J. Pharm. Sci. 65, 1006–1010 (1976)

    Google Scholar 

  • Strong, J. E., Broughton, A., Crooke, S. T.: Specificity of antisera produced against bleomycin. Cancer Treat. Rep. 61, 1509–1512 (1977)

    Google Scholar 

  • Umezawa, H., Maeda, K., Takeuchi, T., Akami, Y.: New antibiotics: bleomycin A and B. J. Antibiot. (Tokyo) 19, 200–209 (1966)

    Google Scholar 

  • Yagoda, A., Mukherji, B., Young, C., Etcubanas, E., Lamonte, C., Smith, J. R., Tan, C. T. C., Krakoff, I. H.: Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients. Ann. Intern. Med. 77, 861–870 (1972)

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alberts, D.S., Chen, H.S.G., Liu, R. et al. Bleomycin pharmacokinetics in man. Cancer Chemother. Pharmacol. 1, 177–181 (1978). https://doi.org/10.1007/BF00253118

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00253118

Keywords

Navigation